{"id":742988,"date":"2023-03-28T07:03:52","date_gmt":"2023-03-28T11:03:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/"},"modified":"2023-03-28T07:03:52","modified_gmt":"2023-03-28T11:03:52","slug":"aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/","title":{"rendered":"ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN MATEO, Calif. and SINGAPORE, March  28, 2023  (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received written notice from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) stating that the Company regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing.<\/p>\n<p>The Company was previously notified by Nasdaq on\u00a0March 28, 2022,\u00a0that it was not in compliance with the minimum bid price requirement because the bid price of\u00a0the Company\u2019s American Depositary Shares (\u201cADSs\u201d) closed below $1.00\u00a0for 30 consecutive business days. In order to regain compliance with the minimum bid price requirement, the Company was required to maintain a minimum closing bid price of\u00a0$1.00\u00a0or more for at least ten consecutive business days, which was achieved on\u00a0March 27, 2023. Accordingly, the Company has regained compliance with Nasdaq\u2019s minimum bid price requirement and the Company\u2019s ADSs will continue to be traded on The Nasdaq Capital Market, subject to the Company\u2019s continued compliance with all applicable continued listing standards.<\/p>\n<p>\n        <strong>About ASLAN Pharmaceuticals<\/strong>\n      <\/p>\n<p>ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN\u00a0is developing <em>eblasakimab<\/em>, a\u00a0potential first-in-class\u00a0antibody\u00a0targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease. <em>Eblasakimab<\/em> is being investigated in a global Phase 2b trial of moderate-to-severe AD patients with topline readout expected in early July 2023. ASLAN is also developing <em>farudodstat<\/em>,\u00a0a potent oral inhibitor of the enzyme DHODH, as a first-in-class treatment for alopecia areata and plans to initiate a proof-of-concept trial in 2Q 2023. ASLAN has teams in San Mateo, California, and in Singapore.\u00a0For additional information please visit\u00a0the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PJy9n6G30WlWEsZusdtNMODAUfmAXtZUMx00pxz9OMhqOc8_pG0peNT9yza5oVQ0fJLNWWnskMjzopB2XQwBOw==\" rel=\"nofollow noopener\" target=\"_blank\">website<\/a> or follow\u00a0ASLAN\u00a0on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eyzY_T7mlxJ4GmRSxXTZsluCvVWuZ5nMFePc6O7u1YVpcSIStAXtYvUWQ8677pxO2WkjQqayt_Ft8-41PqK9g0mNUIgvUbhk9o4WyBoO589u5aq8EHNAUG8rsHU9ZLFu\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Forward looking statements <\/strong>\n      <\/p>\n<p>This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of Company. These forward-looking statements may include, but are not limited to statements regarding the Company\u2019s business strategy and clinical development plans; the Company\u2019s ability to meet the applicable criteria for continued listing on Nasdaq, the Company\u2019s plans to develop and commercialize <em>eblasakimab<\/em> and <em>farudodstat<\/em>; the Company\u2019s plans and expected timing with respect to clinical trials, clinical trial enrolment and clinical trial results for <em>eblasakimab <\/em>and<em> farudodstat<\/em>; and the potential of <em>eblasakimab<\/em> as a first-in-class treatment for atopic dermatitis and of <em>farudodstat<\/em> as a treatment for autoimmune disease. The Company\u2019s estimates, projections and other forward-looking statements are based on management&#8217;s current assumptions and expectations of future events and trends, which affect or may affect the Company\u2019s business, strategy, operations, or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic or the ongoing conflict between Ukraine and Russia on the Company\u2019s business and the global economy; general market conditions; changes in the competitive landscape; and the Company\u2019s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company\u2019s US Securities and Exchange Commission filings and reports (Commission File No. 001- 38475), including the Company\u2019s Annual Report on Form 20-F filed with the US Securities and Exchange Commission on March 24, 2023. All statements other than statements of historical fact are forward-looking statements. The words \u201cbelieve,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201ccould,\u201d \u201cwill,\u201d \u201caim,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cplan,\u201d or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.<\/p>\n<p>\n        <strong> ASLAN Media and IR contacts<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Emma Thompson<\/strong><br \/>\n            <br \/>Spurwing Communications<br \/>Tel: +65 6206 7350 <br \/>Email: <a href=\"mailto:ASLAN@spurwingcomms.com\" rel=\"nofollow noopener\" target=\"_blank\">ASLAN@spurwingcomms.com<\/a><\/p>\n<\/td>\n<td style=\"vertical-align: top\">\n            <strong>Ashley R. Robinson<\/strong><br \/>\n            <br \/>LifeSci Advisors, LLC<br \/>Tel: +1 (617) 430-7577<br \/>Email: <a href=\"mailto:arr@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">arr@lifesciadvisors.com<\/a>\u00a0\u00a0\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjY3MSM1NDk1MjQxIzIwOTU0OTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/M2UxMTE1NTItNWFiYS00ZmYzLWI0NWQtODI5NDNiZDY2NTNmLTExMDcwNjI=\/tiny\/ASLAN-PHARMACEUTICALS-LIMITED.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN MATEO, Calif. and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received written notice from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) stating that the Company regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing. The Company was previously notified by Nasdaq on\u00a0March 28, 2022,\u00a0that it was not in compliance with the minimum bid price requirement because the bid price of\u00a0the Company\u2019s American Depositary Shares (\u201cADSs\u201d) closed below $1.00\u00a0for 30 consecutive business days. In order to regain compliance with the minimum bid price requirement, the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-742988","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN MATEO, Calif. and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received written notice from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) stating that the Company regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing. The Company was previously notified by Nasdaq on\u00a0March 28, 2022,\u00a0that it was not in compliance with the minimum bid price requirement because the bid price of\u00a0the Company\u2019s American Depositary Shares (\u201cADSs\u201d) closed below $1.00\u00a0for 30 consecutive business days. In order to regain compliance with the minimum bid price requirement, the &hellip; Continue reading &quot;ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T11:03:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjY3MSM1NDk1MjQxIzIwOTU0OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements\",\"datePublished\":\"2023-03-28T11:03:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\\\/\"},\"wordCount\":746,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjY3MSM1NDk1MjQxIzIwOTU0OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\\\/\",\"name\":\"ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjY3MSM1NDk1MjQxIzIwOTU0OTE=\",\"datePublished\":\"2023-03-28T11:03:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjY3MSM1NDk1MjQxIzIwOTU0OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjY3MSM1NDk1MjQxIzIwOTU0OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/","og_locale":"en_US","og_type":"article","og_title":"ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements - Market Newsdesk","og_description":"SAN MATEO, Calif. and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received written notice from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) stating that the Company regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing. The Company was previously notified by Nasdaq on\u00a0March 28, 2022,\u00a0that it was not in compliance with the minimum bid price requirement because the bid price of\u00a0the Company\u2019s American Depositary Shares (\u201cADSs\u201d) closed below $1.00\u00a0for 30 consecutive business days. In order to regain compliance with the minimum bid price requirement, the &hellip; Continue reading \"ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-28T11:03:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjY3MSM1NDk1MjQxIzIwOTU0OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements","datePublished":"2023-03-28T11:03:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/"},"wordCount":746,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjY3MSM1NDk1MjQxIzIwOTU0OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/","name":"ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjY3MSM1NDk1MjQxIzIwOTU0OTE=","datePublished":"2023-03-28T11:03:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjY3MSM1NDk1MjQxIzIwOTU0OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjY3MSM1NDk1MjQxIzIwOTU0OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=742988"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742988\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=742988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=742988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=742988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}